Template:Neutropenic fever treatment - Revision history

Danbot: Add pediatric inpatient dosing section

2026-03-20T13:02:33Z

Add pediatric inpatient dosing section

← Older revision		Revision as of 13:02, 20 March 2026
Line 16:		Line 16:
	*{{AntibioticDose\|disease=Neutropenic fever\|drug=Ciprofloxacin\|dose=750mg PO q12hrs\|context=Outpatient\|population=Adult}} AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Amoxicillin/Clavulanate\|dose=875mg PO q12hrs x 7 days\|context=Outpatient with Ciprofloxacin\|population=Adult}} OR<ref name="antibiotics"></ref>		*{{AntibioticDose\|disease=Neutropenic fever\|drug=Ciprofloxacin\|dose=750mg PO q12hrs\|context=Outpatient\|population=Adult}} AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Amoxicillin/Clavulanate\|dose=875mg PO q12hrs x 7 days\|context=Outpatient with Ciprofloxacin\|population=Adult}} OR<ref name="antibiotics"></ref>
	*[[Ciprofloxacin]] 750mg PO q12hrs AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Clindamycin\|dose=450mg PO q8hrs\|context=Outpatient alt with Ciprofloxacin\|population=Adult}}		*[[Ciprofloxacin]] 750mg PO q12hrs AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Clindamycin\|dose=450mg PO q8hrs\|context=Outpatient alt with Ciprofloxacin\|population=Adult}}

			===Pediatric Inpatient===
			*{{AntibioticDose\|disease=Neutropenic fever\|drug=Cefepime\|dose=50mg/kg IV q8hrs (max 2g)\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Neutropenic fever\|drug=Meropenem\|dose=20mg/kg IV q8hrs (max 1g)\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Neutropenic fever\|drug=Piperacillin/Tazobactam\|dose=80-100mg/kg IV q6-8hrs (max 4.5g)\|context=Pediatric Inpatient\|population=Pediatric}}
			*Add {{AntibioticDose\|disease=Neutropenic fever\|drug=Vancomycin\|dose=15mg/kg IV q6hrs\|context=Pediatric, MRSA/catheter\|population=Pediatric}} for same indications as adults

Danbot: Convert to AntibioticDose with disease=Neutropenic fever for SMW linking

2026-03-20T01:30:08Z

Convert to AntibioticDose with disease=Neutropenic fever for SMW linking

← Older revision		Revision as of 01:30, 20 March 2026
Line 2:		Line 2:
	===Inpatient===		===Inpatient===
	*Monotherapy appears to be as good as dual-drug therapy<ref name="antibiotics">Friefeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. 2011; 52(4):e56-93 [http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/FN.pdf fulltext]</ref>		*Monotherapy appears to be as good as dual-drug therapy<ref name="antibiotics">Friefeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. 2011; 52(4):e56-93 [http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/FN.pdf fulltext]</ref>
	**[[Cefepime]] 2g IV ~~q8hr~~ or [[Ceftazidime]] 2g IV ~~q8hr~~ OR		**{{AntibioticDose\|disease=Neutropenic fever\|drug=Cefepime\|dose=2g IV q8hrs\|context=Inpatient monotherapy\|population=Adult}} or {{AntibioticDose\|disease=Neutropenic fever\|drug=Ceftazidime\|dose=2g IV q8hrs\|context=Inpatient monotherapy\|population=Adult}} OR
	**[[Imipenem/~~Cilastin]] 1gm~~ IV ~~q8hr~~ or [[Meropenem~~]] 1gm~~ IV ~~q8hr~~ OR		**{{AntibioticDose\|disease=Neutropenic fever\|drug=Imipenem/Cilastatin\|dose=1g IV q8hrs\|context=Inpatient monotherapy\|population=Adult}} or {{AntibioticDose\|disease=Neutropenic fever\|drug=Meropenem\|dose=1g IV q8hrs\|context=Inpatient monotherapy\|population=Adult}} OR
	**[[Piperacillin/Tazobactam]] 4.~~5gm~~ IV ~~q 6hr~~		**{{AntibioticDose\|disease=Neutropenic fever\|drug=Piperacillin/Tazobactam\|dose=4.5g IV q6hrs\|context=Inpatient monotherapy\|population=Adult}}
	*Consider adding [[Vancomycin]] to above regimen for:<ref>Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Disease 2002; 34:730-751</ref>		*Consider adding [[Vancomycin]] to above regimen for:<ref>Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Disease 2002; 34:730-751</ref>
	**Severe mucositis		**Severe mucositis
Line 14:		Line 14:

	===Outpatient===		===Outpatient===
	*[[Ciprofloxacin]] 750mg PO q12hrs AND [[Amoxicillin/Clavulanate]] 875mg PO q12hrs ~~x7d~~ OR<ref name="antibiotics"></ref>		*{{AntibioticDose\|disease=Neutropenic fever\|drug=Ciprofloxacin\|dose=750mg PO q12hrs\|context=Outpatient\|population=Adult}} AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Amoxicillin/Clavulanate\|dose=875mg PO q12hrs x 7 days\|context=Outpatient with Ciprofloxacin\|population=Adult}} OR<ref name="antibiotics"></ref>
	*[[Ciprofloxacin]] 750mg PO q12hrs AND [[Clindamycin]] 450mg PO q8hrs		*[[Ciprofloxacin]] 750mg PO q12hrs AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Clindamycin\|dose=450mg PO q8hrs\|context=Outpatient alt with Ciprofloxacin\|population=Adult}}

Rossdonaldson1 at 21:32, 11 September 2024

2024-09-11T21:32:54Z

← Older revision		Revision as of 21:32, 11 September 2024
Line 1:		Line 1:
	Therapy is aimed at treating multiple flora that include [[Gram Negatives]], [[Gram Positive Bacteria]], [[Pseudomonas]] and if there is an indwelling catheter or high risk, then [[MRSA]].		''Therapy is aimed at treating multiple flora that include [[Gram Negatives]], [[Gram Positive Bacteria]], [[Pseudomonas]] and if there is an indwelling catheter or high risk, then [[MRSA]].''
	===Inpatient===		===Inpatient===
	*Monotherapy appears to be as good as dual-drug therapy<ref name="antibiotics">Friefeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. 2011; 52(4):e56-93 [http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/FN.pdf fulltext]</ref>		*Monotherapy appears to be as good as dual-drug therapy<ref name="antibiotics">Friefeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. 2011; 52(4):e56-93 [http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/FN.pdf fulltext]</ref>

Ostermayer: Created page with "Therapy is aimed at treating multiple flora that include Gram Negatives, Gram Positive Bacteria, Pseudomonas and if there is an indwelling catheter or high risk, t..."

2015-04-29T11:59:59Z

Created page with "Therapy is aimed at treating multiple flora that include Gram Negatives, Gram Positive Bacteria, Pseudomonas and if there is an indwelling catheter or high risk, t..."

New page

Therapy is aimed at treating multiple flora that include [[Gram Negatives]], [[Gram Positive Bacteria]], [[Pseudomonas]] and if there is an indwelling catheter or high risk, then [[MRSA]].
===Inpatient===
*Monotherapy appears to be as good as dual-drug therapy<ref name="antibiotics">Friefeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. 2011; 52(4):e56-93 [http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/FN.pdf fulltext]</ref>
**[[Cefepime]] 2g IV q8hr or [[Ceftazidime]] 2g IV q8hr OR
**[[Imipenem/Cilastin]] 1gm IV q8hr or [[Meropenem]] 1gm IV q8hr OR
**[[Piperacillin/Tazobactam]] 4.5gm IV q 6hr
*Consider adding [[Vancomycin]] to above regimen for:<ref>Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Disease 2002; 34:730-751</ref>
**Severe mucositis
**Signs of catheter site infection
**[[Fluoroquinolones|Fluoroquinolone]] prophylaxis was recently used against [[gram-negative bacteremia]]
**[[Hypotension]] is present
**Institutions with hospital-associated [[MRSA]]
**Patient has known colonization with resistant [[gram-positive organisms]]

===Outpatient===
*[[Ciprofloxacin]] 750mg PO q12hrs AND [[Amoxicillin/Clavulanate]] 875mg PO q12hrs x7d OR<ref name="antibiotics"></ref>
*[[Ciprofloxacin]] 750mg PO q12hrs AND [[Clindamycin]] 450mg PO q8hrs

← Older revision		Revision as of 13:02, 20 March 2026
Line 16:		Line 16:
	*{{AntibioticDose\|disease=Neutropenic fever\|drug=Ciprofloxacin\|dose=750mg PO q12hrs\|context=Outpatient\|population=Adult}} AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Amoxicillin/Clavulanate\|dose=875mg PO q12hrs x 7 days\|context=Outpatient with Ciprofloxacin\|population=Adult}} OR<ref name="antibiotics"></ref>		*{{AntibioticDose\|disease=Neutropenic fever\|drug=Ciprofloxacin\|dose=750mg PO q12hrs\|context=Outpatient\|population=Adult}} AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Amoxicillin/Clavulanate\|dose=875mg PO q12hrs x 7 days\|context=Outpatient with Ciprofloxacin\|population=Adult}} OR<ref name="antibiotics"></ref>
	*[[Ciprofloxacin]] 750mg PO q12hrs AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Clindamycin\|dose=450mg PO q8hrs\|context=Outpatient alt with Ciprofloxacin\|population=Adult}}		*[[Ciprofloxacin]] 750mg PO q12hrs AND {{AntibioticDose\|disease=Neutropenic fever\|drug=Clindamycin\|dose=450mg PO q8hrs\|context=Outpatient alt with Ciprofloxacin\|population=Adult}}

			===Pediatric Inpatient===
			*{{AntibioticDose\|disease=Neutropenic fever\|drug=Cefepime\|dose=50mg/kg IV q8hrs (max 2g)\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Neutropenic fever\|drug=Meropenem\|dose=20mg/kg IV q8hrs (max 1g)\|context=Pediatric Inpatient\|population=Pediatric}} '''OR'''
			*{{AntibioticDose\|disease=Neutropenic fever\|drug=Piperacillin/Tazobactam\|dose=80-100mg/kg IV q6-8hrs (max 4.5g)\|context=Pediatric Inpatient\|population=Pediatric}}
			*Add {{AntibioticDose\|disease=Neutropenic fever\|drug=Vancomycin\|dose=15mg/kg IV q6hrs\|context=Pediatric, MRSA/catheter\|population=Pediatric}} for same indications as adults